Published in J Immunol on August 30, 2010
Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity (2011) 2.19
Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol (2011) 1.85
Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol (2014) 1.71
Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med (2012) 1.63
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol (2012) 1.44
Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol (2012) 1.21
The role IL-1 in tumor-mediated angiogenesis. Front Physiol (2014) 1.19
Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum (2012) 1.18
From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes (2013) 1.15
Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med (2012) 1.13
Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One (2012) 1.11
Accelerated atherosclerosis in patients with SLE--mechanisms and management. Nat Rev Rheumatol (2012) 1.08
The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol (2014) 1.08
Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol (2012) 1.06
Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol (2013) 0.93
Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis (2016) 0.93
How does interferon-α insult the vasculature? Let me count the ways. Arthritis Rheum (2011) 0.91
The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther (2011) 0.90
Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Res Ther (2013) 0.88
Plasmacytoid dendritic cells in atherosclerosis. Front Physiol (2012) 0.86
Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes. J Biomed Biotechnol (2011) 0.86
What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol (2015) 0.84
Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol (2013) 0.83
Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. Biomed Res Int (2014) 0.82
Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. Rheumatology (Oxford) (2016) 0.82
Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors. Rheumatology (Oxford) (2014) 0.82
Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol (2015) 0.81
IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients. PLoS One (2014) 0.81
Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum (2012) 0.80
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol (2015) 0.80
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheumatol (2017) 0.80
The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov (2016) 0.79
Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78
Refractoriness of interferon-beta signaling through NOD1 pathway in mouse respiratory epithelial cells using the anticancer xanthone compound. World J Biol Chem (2013) 0.75
Modulation of Endothelial Injury Biomarkers by Traditional Chinese Medicine LC in Systemic Lupus Erythematosus Patients Receiving Standard Treatments. Sci Rep (2016) 0.75
Relation of peritubular capillary features to class of lupus nephritis. BMC Nephrol (2016) 0.75
A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those without. BMC Med Genomics (2016) 0.75
Developing Treatments for Chronic Kidney Disease in the 21st Century. Semin Nephrol (2016) 0.75
Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor. Eur J Immunol (2016) 0.75
IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. J Immunol (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum (1992) 14.73
Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol (2009) 14.33
Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03
Caspases: the executioners of apoptosis. Biochem J (1997) 11.99
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 11.50
Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res (2001) 8.62
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 8.14
HuR and mRNA stability. Cell Mol Life Sci (2001) 8.06
Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol (2000) 7.00
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36
Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (1990) 4.87
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol (2005) 4.67
IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A (2003) 3.80
Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum (2006) 3.33
Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res (2001) 3.30
Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum (2004) 3.06
Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes (2006) 2.85
Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation (2003) 2.52
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol (2009) 2.39
A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol (2010) 2.36
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum (1999) 2.36
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol (2007) 2.32
Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol (1991) 2.23
Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol (2007) 2.20
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol (1987) 2.17
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol (2005) 2.16
Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res (2001) 2.05
Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol (2005) 1.95
Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol (2001) 1.90
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. Eur J Immunol (2008) 1.84
Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol (2009) 1.82
Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum (2007) 1.80
Blood monocytes mimic endothelial progenitor cells. Stem Cells (2005) 1.79
Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood (2007) 1.79
Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum (2010) 1.75
Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation (2005) 1.75
Type I IFN protects against murine lupus. J Immunol (2004) 1.71
HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol (2007) 1.68
Microarray analysis of gene expression in lupus. Arthritis Res Ther (2003) 1.67
Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells (2007) 1.66
Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun (2009) 1.66
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol (2009) 1.65
Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol (2004) 1.60
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int (2006) 1.59
Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol (2004) 1.58
Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood (2004) 1.57
Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum (2008) 1.53
Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney Int (2009) 1.53
Mechanism for IL-1 beta-mediated neovascularization unmasked by IL-1 beta knock-out mice. J Mol Cell Cardiol (2004) 1.51
Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol (2004) 1.50
NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J Am Soc Nephrol (2010) 1.49
IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int Immunol (2003) 1.46
Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol (2005) 1.45
Synergistic effects of asymmetrical dimethyl-L-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up in stable angina. Nephrol Dial Transplant (2009) 1.43
Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab (2007) 1.39
Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res (1996) 1.36
Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum (2007) 1.36
Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ Res (2008) 1.35
A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J Immunol (1986) 1.30
Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol (2005) 1.28
Etiopathogenesis of systemic lupus erythematosus. Immunol Today (2000) 1.26
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 1.24
IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol (2003) 1.23
Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw (1997) 1.23
IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol (2008) 1.22
Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum (2008) 1.21
Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus (2010) 1.20
Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med (1981) 1.20
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum (2002) 1.18
Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res (2009) 1.17
Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol (2003) 1.16
Signaling lymphocytic activation molecule is expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta. J Immunol (2001) 1.16
Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A (1992) 1.15
Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.14
Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol (2000) 1.13
Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis (2004) 1.13
A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J Biol Chem (2002) 1.10
Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J (2003) 1.10
IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine (2001) 1.09
Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun (2007) 1.09
IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J Immunol (2002) 1.06
Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production. Mol Pharmacol (2005) 1.06
Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J Immunol (2004) 1.04
Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol (2009) 1.04
Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis (2004) 1.03
Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol (2009) 1.03
Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro. J Cereb Blood Flow Metab (2009) 1.02
Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol (2003) 1.02
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun (2008) 1.01
IL-1 beta induces dendritic cells to produce IL-12. Int Immunol (2001) 1.01
Cell biology of the glomerular podocyte. Physiol Rev (2003) 6.85
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest (2007) 4.80
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 3.83
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med (2013) 3.70
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. Kidney Int (2003) 2.90
Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes (2006) 2.85
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest (2011) 2.72
Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med (2006) 2.65
Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol (2011) 2.53
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol (2008) 2.41
A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol (2010) 2.36
Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int (2002) 2.34
Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol (2006) 2.32
Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol (2007) 2.20
Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes (2008) 2.07
Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest (2007) 2.02
Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol (2002) 1.96
Defining cell-type specificity at the transcriptional level in human disease. Genome Res (2013) 1.96
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol (2004) 1.85
Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol (2011) 1.85
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood (2007) 1.79
An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol (2014) 1.78
Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier. J Am Soc Nephrol (2009) 1.77
Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis (2006) 1.73
Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol (2006) 1.72
Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int (2004) 1.72
Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes (2013) 1.71
A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest (2002) 1.70
Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol (2006) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol (2005) 1.69
Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol (2009) 1.65
From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes (2008) 1.65
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 1.64
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J (2004) 1.60
Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther (2012) 1.57
Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood (2004) 1.57
Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol Dial Transplant (2006) 1.55
Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol (2003) 1.54
Women in academic rheumatology. Arthritis Rheum (2005) 1.49
NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J Am Soc Nephrol (2010) 1.49
Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol (2012) 1.48
A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis. J Clin Invest (2016) 1.48
Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta (2007) 1.44
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol (2008) 1.44
Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol (2012) 1.44
Vitamin D deficiency, interleukin 17, and vascular function in rheumatoid arthritis. J Rheumatol (2013) 1.44
Comparative promoter analysis allows de novo identification of specialized cell junction-associated proteins. Proc Natl Acad Sci U S A (2006) 1.43
Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.41
Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes (2012) 1.39
Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis. Kidney Int (2005) 1.35
Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol (2006) 1.33
Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol (2005) 1.32
Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol (2006) 1.28
Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol (2006) 1.28
Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int (2013) 1.27
Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS One (2008) 1.27
Human nephrosclerosis triggers a hypoxia-related glomerulopathy. Am J Pathol (2009) 1.27
Kindlin-2 regulates podocyte adhesion and fibronectin matrix deposition through interactions with phosphoinositides and integrins. J Cell Sci (2011) 1.27
Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J (2006) 1.27
CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol (2005) 1.26
A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol (2011) 1.25
Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J Am Soc Nephrol (2003) 1.25
Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr Opin Rheumatol (2012) 1.25
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest (2012) 1.25
The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol (2008) 1.25
Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One (2011) 1.24
Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clin J Am Soc Nephrol (2013) 1.24
CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int (2004) 1.24
Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol (2004) 1.23
Spatial and temporally restricted expression of chemokines and chemokine receptors in the developing human kidney. J Am Soc Nephrol (2002) 1.23
The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol (2008) 1.22
Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis, and tissue homeostasis. J Immunol (2002) 1.21
Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int (2003) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol (2012) 1.21